Agalsidase Benefits Renal Histology in Young Patients with Fabry Disease

The effect of early-onset enzyme replacement therapy on renal morphologic features in Fabry disease is largely unknown. Here, we evaluated the effect of 5 years of treatment with agalsidase alfa or agalsidase beta in 12 consecutive patients age 7–33 years (median age, 16.5 years). We performed renal...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Tøndel, Camilla, Bostad, Leif, Larsen, Kristin Kampevold, Hirth, Asle, Vikse, Bjørn Egil, Houge, Gunnar, Svarstad, Einar
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Nephrology 2012
Témata:
Clinical Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3537211/
https://ncbi.nlm.nih.gov/pubmed/23274955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2012030316
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky